Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 625-638 , August 2008

Insulin, insulin-like growth factors and neoplasia

References 

  1. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nature Reviews. Cancer. 2004;4:505–518
  2. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Molecular Cancer Therapeutics. 2007;6:1–12
  3. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opinion on Therapeutic Targets. 2008;12:589–603
  4. Dong MQ, Venable JD, Au N, et al. Quantitative mass spectrometry identifies insulin signaling targets in c. elegans. Science. 2007;317:660–663
  5. De Souza AT, Hankins GR, Washington MK, et al. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nature Genetics. 1995;11:447–449
  6. Kaneda A, Wang CJ, Cheong R, et al. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:20926–20931
  7. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science. 1997;276:1268–1272
  8. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Current Pharmaceutical Design. 2007;13:671–686
  9. Benyoucef S, Surinya KH, Hadaschik D, et al. Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. The Biochemical Journal. 2007;403:603–613
  10. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Archives of Insect Biochemistry and Physiology. 2008;114:23–37
  11. Ohsugi M, Cras-Meneur C, Zhou Y, et al. Reduced expression of the insulin receptor in mouse insulinoma (MIN6) cells reveals multiple roles of insulin signaling in gene expression, proliferation, insulin content, and secretion. The Journal of Biological Chemistry. 2005;280:4992–5003
  12. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews. 2002;23:824–854
  13. Sitar T, Popowicz GM, Siwanowicz I, et al. Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:13028–13033
  14. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. The Journal of Clinical Investigation. 2008;118(7):2609–2619
  15. Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:5563–5568
  16. Levitt RJ, Georgescu MM, Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochemical and Biophysical Research Communications. 2005;336:1056–1061
  17. Osborne CK, Bolan G, Monaco ME, et al. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proceedings of the National Academy of Sciences of the United States of America. 1976;73:4536–4540
  18. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Research. 1972;32:226–232
  19. Hede K. Doctors seek to prevent breast cancer recurrence by lowering insulin levels. Journal of the National Cancer Institute. 2008;100:530–532
  20. Pollak M, Perdue JF, Margolese RG, et al. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Letters. 1987;38:223–230
  21. Myal Y, Shiu RP, Bhaumick B, et al. Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture. Cancer Research. 1984;44:5486–5490
  22. Majeed N, Blouin MJ, Kaplan-Lefko PJ, et al. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene. 2005;24:4736–4740
  23. Wu Y, Cui K, Miyoshi K, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Research. 2003;63:4384–4388
  24. Pollak M, Blouin MJ, Zhang JC, et al. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone anatgonist. British Journal of Cancer. 2001;85:428–430
  25. Goya M, Miyamoto S, Nagai K, et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Research. 2004;64:6252–6258
  26. Haluska P, Carboni JM, Loegering DA, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Research. 2006;66:362–371
  27. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Molecular Cancer Therapeutics. 2007;6:2158–2167
  28. Rowinsky EK, Youssoufian H, Tonra JR, et al. A human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clinical Cancer Research. 2007;13:5549s–5555s
  29. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clinical Cancer Research. 2005;11:2063–2073
  30. Venkateswaran V, Haddad AQ, Fleshner NE, et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. Journal of the National Cancer Institute. 2007;99:1793–1800
  31. Stavola BL, Hardy R, Kuh D, et al. Birthweight, childhood growth and risk of breast cancer in British cohort. British Journal of Cancer. 2000;83:964–968
  32. McCormack VA, dos Santos Silva I, De Stavola BL, et al. Fetal growth and subsequent risk of breast cancer: results from long term follow up of Swedish cohort. BMJ. 2003;326:248
  33. Sandhu MS, Luben R, Day NE, et al. Self-reported birth weight and subsequent risk of colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention. 2002;11:935–938
  34. Tibblin G, Eriksson M, Cnattingius S, et al. High birthweight as a predictor of prostate cancer risk. Epidemiology. 1995;6:423–424
  35. Von Behren J, Reynolds P. Birth characteristics and brain cancers in young children. International Journal of Epidemiology. 2003;32:248–256
  36. Vatten LJ, Nilsen ST, Odegard RA, et al. Insulin-like growth factor-I and leptin in umbilical cord plasma and infant birth size at term. Pediatrics. 2002;109:1131–1135
  37. Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950 000 Norwegian men. British Journal of Cancer. 2003;89:1237–1242
  38. Gunnell D, Okasha M, Smith GD, et al. Height, leg length, and cancer risk: a systematic review. Epidemiologic Reviews. 2001;23:313–342
  39. Lawlor DA, Okasha M, Gunnell D, et al. Associations of adult measures of childhood growth with breast cancer: findings from the British women's heart and health study. British Journal of Cancer. 2003;89:81–87
  40. Ahlgren M, Melbye M, Wohlfahrt J, et al. Growth patterns and the risk of breast cancer in women. The New England Journal of Medicine. 2004;351:1619–1626
  41. Diorio C, Pollak M, Byrne C, et al. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiology. 2005;14:1065–1073
  42. Byrne C, Colditz GA, Willett WC, et al. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Research. 2000;60:3744–3748
  43. Ma J, Pollak M, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I, and IGF-binding protein-3. Journal of the National Cancer Institute. 1999;91:620–625
  44. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiology, Biomarkers & Prevention. 2000;9:345–349
  45. Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor-1, insulin-like growth factor binding protein-3, and risk of colorectal cancer: a prospective study in Northern Sweden. Gut. 2002;50:642–646
  46. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:563–566
  47. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. Journal of the National Cancer Institute. 2002;94:1099–1106
  48. Harman SM, Metter EJ, Blackman MR, et al. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. The Journal of Clinical Endocrinology and Metabolism. 2000;85:4258–4265
  49. Stattin P, Bylund A, inaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. Journal of the National Cancer Institute. 2000;92:1910–1917
  50. Schernhammer ES, Holly JM, Hunter DJ, et al. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in the nurses health study II. Endocrine-Related Cancer. 2006;13:583–592
  51. Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochimica Et Biophysica Acta. 2006;766:1–22
  52. Miller AB. Commentary: implications of the frequent occurrence of occult carcinoma of the prostate. International Journal of Epidemiology. 2007;36:282–284
  53. Nam RK, Zhang WW, Trachtenberg J, et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention. 2003;12:1429–1437
  54. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–1353
  55. Cheng I, Stram DO, Penney KL, et al. Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. Journal of the National Cancer Institute. 2006;98:123–134
  56. Johansson M, McKay JD, Wiklund F, et al. Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. The Journal of Clinical Endocrinology and Metabolism. 2007;92:4820–4826
  57. Suh Y, Atzmon G, Cho MO, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:3438–3442
  58. Ma J, Li H, Giovannucci E, et al. A long term survival analysis of prediagnostic body mass index, plasma C-peptide levels, and prostate cancer specific mortality among men with prostate cancer. Lancet Oncology, in press.
  59. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. Journal of Clinical Oncology. 2002;20:42–51
  60. Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict?. Cancer Causes Control. 2006;17:5–9
  61. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. The American Journal of Clinical Nutrition. 2007;86:s836–s842
  62. Pollak M, Chapman J, Shepherd L, et al. Insulin resistance estimated by serum c-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC-CTG MA14 adjuvant breast cancer trial. (Podium presentation). 2006. ASCO Meeting Preceedings Part I Journal of Clinical Oncology. 2006;vol. 24:524;No. 18S (June 20 Suppl.)
  63. Cox M, Gleave M, Zakikhani M, et-al. Insulin receptor expression by human prostate cancers. The Prostate, in press.
  64. Algire C, Zakikhani M, Blouin M-J, et al. Metformin attenuates the stimulatory effect of a high energy diet on in vivo H59 carcinoma growth. Endocrine-Related Cancer. 2008;[Epub ahead of print]
  65. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology. 2008;110:246–250
  66. Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research. 2007;67:10804–10812
  67. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research. 2006;66:10269–10273
  68. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England Journal of Medicine. 2003;348:1625–1638
  69. Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. (Editorial). Lancet. 2002;360:268–269
  70. Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958–1998. Radiation Research. 2007;168:1–64
  71. Pollak MN, Chapman JW, Pritchard KI, et al. NCIC-CTG MA14 trial: tamoxifen (tam) vs. tam+octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer. Proceedings of ASCO Journal of Clinical Oncology. 2008;26:(May 20 suppl; abstr 532)
  72. Weckbecker G, Tolcsvai L, Stolz B, et al. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Research. 1994;54:6334–6337
  73. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic and pharmacodynamic study of weekly MK-0646, an insulin-like growth factor-1 receptor monoclonal antibody in patients with advanced solid tumors. Proceedings of ASCO Journal of Clinical Oncology. 2008;26:(May 20 suppl. abstr 3519)
  74. Olmos D, Okuno S, Schuetze SM, et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. Proceedings of ASCO Journal of Clinical Oncology. 2008;26:(May 20 suppl; abstr 10501)
  75. Gualberto A, Melvin CL, Dean A, et al. Characterization of NSCLC patients responding to anti-IGF-IR therapy. Proceedings of ASCO Journal of Clinical Oncology. 2008;26:(May 20 suppl; abstr 8000)
  76. Karp DD, Paz-Ares LG, Novello S, et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. Proceedings of ASCO Journal of Clinical Oncology. 2008;26:(May 20 suppl; abstr 8015)
  77. Lacy MQ, Alsina M, Fonseca R, et al. Pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. Journal of Clinical Oncology. 2008;26:3196–3203
  78. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clinical Cancer Research. 2007;13:5834–5840
  79. De Bono JS, Attard G, Adjei A, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clinical Cancer Research. 2007;13:3611–3616
  80. Yin D, Paccagnella ML, Lacy MQ, et al. Population pharmacokinetics of CP-751,871, a monoclonal antibody against IGF-I receptor, in patients with multiple myeloma or solid tumors. Proceedings of ASCO Journal of Clinical Oncology. 2008;26:(May 20 suppl; abstr 2524)
  81. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo anti-tumor activity of NVP-AEW541-A novel, potent and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004;5:231–239
  82. Zhang H, Pelzer AM, Kiang DT, et al. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Research. 2007;67:391–397
  83. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). Journal of the National Cancer Institute. 2001;93:1852–1857
  84. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer. 2004;11:793–814
  85. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932–1940
  86. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research. 2006;66:1500–1508
  87. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–1646
  88. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–258
  89. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–1305
  90. Jiralerspong S, Giordano SH, Meric-Bernstam F, et al. The effects of metformin on pathologic complete response rates in diabetic breast cancer patients receiving neoadjuvant systemic therapy. Proceedings of ASCO Journal of Clinical Oncology. 2008;26:(May 20 suppl; abstr 528)
  91. Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Research and Treatment. 2008;[Epub ahead of print]
  92. Kopchick JJ. Discovery and development of a new class of drugs: GH antagonists. Journal of Endocrinological Investigation. 2003;26:16–26

PII: S1521-690X(08)00090-0

doi: 10.1016/j.beem.2008.08.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 625-638 , August 2008

Article Tools